The research groups of Professor Hendrik Fuchs (Charité University, Berlin, Germany) and Dr David Flavell (Southampton General Hospital, United Kingdom) are working together toward the development of Gypsophila saponins for use in combination with immunotoxins or other targeted toxins for patients with leukaemia, lymphoma and other cancers.
saponin |
The company is in the early stages of developing a telomerase based treatment for HIV called TAT0002, which is the saponin cycloastragenol in Chinese herb Astragalus propinquus.